Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)

NCT04853251 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT04853251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04853251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)
Lead sponsor
Genentech, Inc.
Phase
Phase 4
Overall status
Recruiting
Start date
December 14, 2021
Completion date
August 31, 2027
Enrollment
188 (estimated)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration